• Press Releases.png

    Press Releases

AXIS Clinicals Signs Three Year Agreement for OmniComm Systems’® TrialOne®

May 12, 2014


Dennis Constantinou
OmniComm Systems, Inc.

Download Press Release

State-of-the-art clinic selects TrialOne for clinic automation

Fort Lauderdale, FL, May 12, 2014 –- OmniComm Systems, Inc. (OTCQB: OMCM), a global leading provider of clinical data management solutions for clinical trials, today announced a three year agreement for TrialOne with AXIS Clinicals, a global contract research organization. AXIS Clinicals selected TrialOne to standardize their processes, improve their business intelligence, ensure regulatory compliance, and achieve overall business transformation at its US based 300 bed clinic.

TrialOne is a fully browser-based bedside data collection technology designed specifically to address the needs of Phase I clinics. AXIS Clinicals will take full advantage of TrialOne’s subject recruitment, study data capture, sample tracking, reporting, data management and integration with laboratory and medical monitoring equipment capabilities. Furthermore, TrialOne’s import and export features provide integration with laboratory information management systems for lab orders and results processing.

TrialOne will enable AXIS Clinicals to automate their data collection; standardize recruiting; collect study data and track samples; reduce discrepancies inherent in paper-based applications; and ensure regulatory compliance. TrialOne’s ability to capture data directly from the patient bedside makes it a true eSource data collection tool that aligns perfectly with recent FDA guidance on eSource. As a single source of data collection from external sources such as laboratory, centralized ECG system or patient diaries, TrialOne provides AXIS Clinicals with the ability to immediately process, display and review information from all of these data sources in TrialOne.

“TrialOne is an excellent addition to our new state-of-the-art facility in Dilworth, Minnesota,” said Sidharth Mishra, director business development, AXIS Clinicals. “We hope to be the CRO of choice for our sponsors with a high level of regulatory compliance and the full end to end automation which comes with the TrialOne software."

“AXIS Clinicals’ selection reinforces TrialOne as the market leading Phase I clinic automation technology,” said Dr. Kuno van der Post, senior vice president business development, OmniComm Systems. “Time and efficiency are imperative to our Phase I clinic clients and they have to be able to depend entirely on robust and reliable technology that offers optimal performance.”

Supporting Information

About OmniComm Systems

OmniComm Systems, Inc. (www.OmniComm.com) provides customer-driven Internet solutions to pharmaceutical, biotechnology, research and medical device organizations that conduct life changing clinical trial research. OmniComm's growing base of satisfied customers is a direct result of the company's commitment to deliver products and services that ensure ease of use, faster study build, ease of integration and better performance. OmniComm's pricing model is easily understood and allows companies ranging from small, to large, to maximize their clinical research investments. OmniComm Systems, Inc. has U.S. headquarters in Fort Lauderdale, FL and European headquarters in Bonn, Germany, with satellite offices in New Jersey and the United Kingdom, as well as sales offices throughout the U.S. and Europe.

Safe Harbor Disclaimer

Statements made by OmniComm included in this release may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements involve a number of risks and uncertainties such as the Company's ability to obtain new contracts and accurately estimate net revenues due to uncertain regulatory guidance, variability in size, scope and duration of projects, and internal issues at the sponsoring client, integration of acquisitions, competitive factors, technological development, and market demand. As a result, actual results may differ materially from any financial outlooks stated herein. Further information on potential factors that could affect the Company's financial results can be found in the Company's Reports on Form 10-K and 10-Q filed with the Securities and Exchange Commission. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.


OmniComm and TrialMaster are registered trademarks of OmniComm Systems, Inc. Other names may be trademarks of their respective owners.